Revenue
2019
2020
2021
2022
2023
2024
2025
NovaBridge Biosciences (NBP)
Price$1.79Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $632,000 | −$1.6M | $13.8M | $236.4M | $4.3M | — | — |
| Gross profit | — | — | — | −$5.5M | $6.5M | — | — | — | — |
| Gross margin | — | — | — | — | 47.25% | — | — | — | — |
| Research & development | $62.9M | $21.8M | $21.4M | $22.5M | $190.3M | $150.9M | $120.7M | — | — |
| Operating expenses | $94.3M | $51.4M | $72.6M | $51.5M | — | — | — | — | — |
| Operating income | −$94.3M | −$51.4M | −$72.0M | −$53.1M | — | — | — | — | — |
| Operating margin | — | — | −11,395.09% | — | — | — | — | — | — |
| EBITDA | −$94.2M | −$51.1M | −$71.5M | −$52.9M | — | — | — | — | — |
| EBITDA margin | — | — | −11,315.98% | — | — | — | — | — | — |
| Net income | −$46.3M | −$22.2M | −$207.7M | −$371.1M | −$365.9M | $72.2M | −$208.6M | — | — |
| Net profit margin | — | — | −32,868.51% | — | −2,648.74% | 30.53% | −4,840.10% | — | — |
| Basic EPSper basic share | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$2.09 | $0.54 | -$28.90 | — | — |
| Diluted EPSper diluted share | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$2.09 | $0.46 | -$28.90 | — | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Fu Wei | 30.5M |
HHLR ADVISORS, LTD. | 5.98M |
MORGAN STANLEY | 3.65M |
AIHC Capital Management Ltd | 2.88M |
Siren, L.L.C. | 2M |
MARSHALL WACE, LLP | 1.23M |
Candriam S.C.A. | 1.13M |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1M |
Zhang Xiaofan Neo | 874K |
TWO SIGMA INVESTMENTS, LP | 851.35K |
RENAISSANCE TECHNOLOGIES LLC | 758.23K |
BlackRock, Inc. | 686.21K |
CITADEL ADVISORS LLC | 622.83K |
E Fund Management Co., Ltd. | 589.02K |
Exome Asset Management LLC | 576.96K |
STATE STREET CORP | 360.38K |
Woodline Partners LP | 350K |
Fiera Capital Corp | 315.68K |
UBS Group AG | 301.78K |
Xu Cong Claire | 290.15K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 | Dennis Phillip AndrewChief Medical Officer | SellOrdinary Shares | 8.5K | $0.66 | $5.6K | 157.9K |
| Jun 1, 2026Form 4 | Xu Cong ClaireSVP, Clinical Development | SellOrdinary Shares | 3.5K | $3.94 | $13.8K | 290.2K |
| May 14, 2026Form 4 | Cao Sean WuxiongSee Remarks | SellOrdinary Shares | 21.4K | $1.99 | $42.6K | 35.1K |
| Apr 24, 2026Form 4 | Hagler Mark ArnoldSee Remarks | BuyOrdinary Shares | 230.0K | $2.51 | $577.3K | 230.0K |